All Merck Articles
U.S.-Based GeoVax Emerges as Key Monopoly Challenger Amid $2.99B Bavarian Nordic Takeover – ($GOVX $IBB $XBI)
Bavarian Nordic, a leading Danish vaccine manufacturer best known for its MVA-BN (Modified Vaccinia Ankara–Bavarian Nordic) smallpox and mpox vaccines, recently agreed to a $2.99 billion takeover by private equity firms Permira and Nordic Capital. Shareholders are being offered 233 Danish kroner ...
Jul 31, 2025
View Article
Merck Sets Its Sights on Eyebiotech: Pharma Giant Eyes $1.3 Billion Move Into Vision Care
Merck (MRK) is setting its sights on a new frontier—your eyes. The pharmaceutical heavyweight is on the verge of acquiring Eyebiotech, an ophthalmology biotech upstart, in a deal valued at a crisp $1.3 billion. If finalized, this move would mark Merck’s debut into the bustling world o...
Jul 11, 2025
View Article
Serina Therapeutics: Optimizing Drug Delivery for the Future – ( $SER )
Serina Therapeutics (NYSE: SER) is positioning itself at the forefront of a new era in drug development, as highlighted in a recent corporate video titled "Rethinking Drug Development: Faster, Smarter, Strategic and reinforced by a series of strategic moves and partnerships. Rather than reinvent...
Jul 07, 2025
View Article
Modular Medical (Nasdaq: MODD) Unveils Updated Investor Presentation, Emphasizing Disruptive Business Model and Near-Term Milestones
Over the weekend, Modular Medical, Inc. (Nasdaq: MODD), a San Diego-based innovator in insulin delivery technology, quietly published an updated investor presentation, signaling a new phase in its campaign to transform diabetes care. The release comes on the heels of the company’s recent scien...
Jun 30, 2025
View Article
GeoVax Applauds FDA’s Green Light for Keytruda: A New Chapter in Head and Neck Cancer—and a Wink at Gedeptin’s Future – ( $GOVX $MRK $XBI )
In the ever-evolving world of oncology, every so often a regulatory decision comes along that feels less like a footnote and more like a new chapter. The U.S. Food and Drug Administration’s (FDA) recent approval of Merck’s (MRK) Keytruda® (pembrolizumab) for resectable, locally advanced hea...
Jun 24, 2025
View Article
The Biotech World Is Buzzing With A ‘Bispecific Bonanza’ – ( $AZN $BNTX $BMY $MRK $PFE )
The biotech world is buzzing with a 'bispecific bonanza' as industry heavyweights and nimble startups alike double down on these dual-targeting marvels. Leading the charge on Monday, BioNTech (BNTX) and Bristol Myers Squibb (BMY) just inked a $11.1 billion tango to co-develop BNT327, a bispecifi...
Jun 02, 2025
View Article
Bacteria In The Limelight: Indaptus Therapeutics’ Decoy20 Takes Center Stage With Cancer Immunotherapy PD-1 Inhibitor Combination- ( $INDP $ONC $MRK $XBI )
In the ever-evolving world of biotech innovation, Indaptus Therapeutics (NASDAQ: INDP) has once again taken center stage—this time with the dosing of the first patient in its expansion arm of a Phase 1b/2 clinical trial. The star of the show? Decoy20, a novel immunotherapy candidate that’s l...
Jun 02, 2025
View Article
GeoVax Labs’ Manufacturing: Homegrown and Ready to Scale In The U.S.A. – ( $GOVX $IBB $XBI )
GeoVax Labs, Inc. (NASDAQ: GOVX) is taking a well-deserved victory lap as the U.S. Senate moves forward with bipartisan legislation to bolster America’s domestic vaccine manufacturing muscle—a development that aligns perfectly with GeoVax’s own ambitions and expertise6. Let’s take a clos...
May 29, 2025
View Article
GeoVax Successfully Adds To Burgeoning Intellectual Property Portfolio – $GOVX $MRK $XBI
GeoVax Labs, Inc. (NASDAQ: GOVX), a trailblazer in the biotechnology arena, is steadily carving its niche in the development of vaccines and immunotherapies targeting infectious diseases and cancers. The company recently celebrated a significant milestone: the U.S. Patent and Trademark Office (USPTO...
Apr 09, 2025
View Article
Discover IN8bio’s Potentially Breakthrough Next Generation γδ T cell-based T cell engager (TCE) Platform At AACR 2025 – $INAB $IBB $XBI $SNY
IN8bio, Inc. (Nasdaq: INAB), a trailblazer in gamma-delta T cell-based therapies, is turning heads at the forefront of cancer immunotherapy with its latest preclinical findings. Just this week, the company unveiled a poster presentation on its potentially breakthrough next generation γδ T cell-bas...
Apr 01, 2025
View Article
Vista Alert: Indaptus Therapeutics Offers Novel Immunotherapy Decoy20 Cancer Treatment Progress Update – $INDP $MRK $NVS $PFE $XBI
Decoy20 represents a novel approach to cancer immunotherapy. Unlike current treatments that target specific immune pathways, Decoy20 aims to activate a broad antitumor response from both innate and adaptive immune systems. Composed of attenuated and killed non-pathogenic Gram-negative bacteria, Deco...
Sep 08, 2024
View Article
Pharma’s Evolving 2024 Acquisition Spree – $ABBV $EPRX $GILD $JNJ $LLY $MRK $NVS $VRTX
Based on reports from The Wall Street Journal, major pharmaceutical companies are shifting their focus to smaller acquisitions in 2024, with all 17 deals announced in the first half of the year valued at $5 billion or less, reflecting a changing regulatory landscape and a more selective approach to ...
Aug 21, 2024
View Article
Merck’s Prevymis Earns European Approval For Kidney Transplant Recipient Care – $MRK $DIA $IBB $LTRN
Reportedly, Merck & Co., Inc. (MRK) announced that the European Union medicines regulator has recommended granting marketing authorization for their medication, Prevymis, aimed at treating a specific infection in adult kidney transplant recipients at a high risk. Furthermore, the Committee for M...
Oct 18, 2023
View Article
Merck Exceeds Revenue Estimates With Strong Sales Of Keytruda & Gardasil In Q2 2023 – $MRK $DIA $IBB $LTRN
Reportedly, Merck & Co., Inc. (MRK) second-quarter revenue exceeded estimates, primarily driven by strong sales of its cancer drug Keytruda and HPV vaccine Gardasil. However, the company swung to a net loss of $5.98 billion, or $2.35 per share, from the previous year's net income of $3.94 billio...
Sep 18, 2023
View Article
Merck Approves $0.73 Per Share Dividend For Q3 2023 – $MRK $DIA $IBB $INVO
As per reports, the board of Merck & Co., Inc. (MRK) announced its quarterly dividend for the third quarter of 2023. The board has authorised a dividend of $0.73 per share for the common stock. Shareholders who are officially listed as such by the end of business on June 15, 2023, will be eligib...
Jun 16, 2023
View Article
Merck’s Q1 2023 Sales & Earnings Call On April 27 – $MRK $DIA $IBB $INVO
Merck & Co., Inc. (MRK) will host a conference call on April 27, 2023 at 9:00 a.m. ET for institutional investors and analysts to discuss the company's sales and earnings for the first quarter. The call will feature an overview of the quarter's performance by company executives. A live audio web...
Apr 04, 2023
View Article
Stay Informed. Stay Competitive.
Vista Partners offers an exclusive newsletter and content with daily, weekly, monthly and quarterly investing ideas, strategies, and marketing insights.
We value your privacy and will never share your information.
